Eli Lilly and Company Data Analyst Salaries in Rocky Mount, NC
The average Eli Lilly and Company Data Analyst in Rocky Mount, NC earns $127,000 annually, which includes a base salary of $120,000 with a $7,000 bonus. This total compensation is $49,395 more than the US average for a Data Analyst.
In Rocky Mount, NC, The Marketing Department at Eli Lilly and Company earns $3,562 more on average than the Operations Department. Comparably data has a total of 1 salary record from Eli Lilly and Company Data Analysts.
Last updated 4 months ago.
- $120,000
- avg. base
- $7,000
- avg. bonus
- 0-10K
- equity range
Data Analyst Salaries at Eli Lilly and Company
In Rocky Mount, NC, Data Analysts earn $9,863 more than Brand Managers, and $19,715 less than Global Marketing Managers.
Compensation at Eli Lilly and Company by Department
In Rocky Mount, NC, The Marketing Department averages $3,562 more than the Operations Department, and $6,278 less than the Engineering Department
Average Equity for Data Analyst at Eli Lilly and Company
In Rocky Mount, NC, the average Data Analyst at Eli Lilly and Company receives $10K of stock in equity.
Recent Data Analyst Salaries at Eli Lilly and Company
Data Analyst Compensation by Gender (All Companies)
The average female Data Analyst at companies similar size to Eli Lilly and Company reported making $84,822, while the average male Data Analyst at similar sized companies reported making $95,395.
Data Analyst Compensation by Ethnicity (All Companies)
The average Asian or Pacific Islander Data Analyst at companies similar size to Eli Lilly and Company reported making $91,469, while the average African American/Black Data Analyst at similar sized companies reported making $64,333.
How Data Analysts at Eli Lilly and Company Rate Their Compensation
The majority of Data Analysts at Eli Lilly and Company believe they're compensated fairly. 100% of Data Analysts at Eli Lilly and Company say they receive annual bonuses, and the vast majority (83%) are satisfied with their benefits. See more compensation ratings at Eli Lilly and Company
